Allakos

ALLK49

Penny Stock

$0.57arrow_drop_up6.72%$0.03

Penny Stock

ALLK49

$0.57

arrow_drop_up6.72%$0.03

Penny Stock

Performance History

Key Stats
Open	$0.56
Prev. Close	$0.54
EPS	-2.35
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-
Market Cap	$47.97M
PE Ratio	-

	LOW	HIGH
Day Range	0.55	0.63
52 Week Range	0.54	3.41

Ratios

Revenue	-



EBITDA Margin %	-

EPS	-2.35

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Allakos (ALLK)

Allakos Inc (ALLK) is a clinical stage biotechnology company that specializes in the development of therapeutic antibodies for the treatment of various allergic and inflammatory diseases. The company's lead product candidate is AK002, which is being evaluated for the treatment of eosinophilic gastritis and eosinophilic duodenitis, conditions characterized by an excessive accumulation of eosinophils in the stomach and duodenum. AK002 is also being studied for the treatment of allergic conjunctivitis and allergic asthma. The company has a strong pipeline of other product candidates targeting different diseases.

ALLK stock has had a volatile price history since the company went public in 2018. It initially gained significant attention from investors due to the potential of its unique antibody therapies. However, the stock price has experienced fluctuations in response to clinical trial results and market sentiment. It is important for investors to carefully analyze the company's financials and the progress of its clinical trials to make informed investment decisions.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Dr. Robert Alexander Ph.D.
Headquarters: San Carlos
Employees: 123
Exchange: NASDAQ

Keep an eye on Allakos

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is the market capitalization of Allakos (ALLK)?

Allakos (ALLK) has a market capitalization of $47.98M. The average daily trading volume is 374.39K, indicating the stock's liquidity and investor engagement.

help

What is Allakos 's (ALLK) price per share?

The current price per share for Allakos (ALLK) is $0.58. The stock has seen a price change of $0.04 recently, indicating a 6.72% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Allakos (ALLK)?

For Allakos (ALLK), the 52-week high is $3.41, which is 491.71% from the current price. The 52-week low is $0.54, the current price is 6.72% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Allakos (ALLK) a growth stock?

Allakos (ALLK) has shown an average price growth of 0.41% over the past three years. It has received a score of 3 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Allakos as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Allakos (ALLK) stock price performance year to date (YTD)?

As of the latest data, Allakos (ALLK) has a year-to-date price change of -78.97%. Over the past month, the stock has experienced a price change of -19.17%. Over the last three months, the change has been -48.54%. Over the past six months, the figure is -53.15%. Looking at a longer horizon, the five-year price change stands at -99.29%.

help

Is Allakos (ALLK) a profitable company?

Allakos (ALLK) has a net income of -$185.7M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$196.06M. Furthermore, the EBITDA is -$182.51M.

News

Allakos Provides Business Update and Reports Second Quarter 2024 Financial Results

ALLAKOS INC.

AK006

CHRONIC SPONTANEOUS URTICARIA

FINANCIAL RESULTS

8/7/2024

Allakos Provides Business Update and Reports Second Quarter 2024 Financial Results

HEALTH

RESEARCH ANALYSIS AND REPORTS

6/25/2024

Allakos Announces Positive Results from its Ongoing Phase 1 Trial of AK006 in Healthy Volunteers, with AK006 Demonstrating High Receptor Occupancy on Mast Cells and a Favorable Safety Profile